The FDA's new Quality Management System Regulation (QMSR) is finally here, aligning US regulations with the global ISO 13485 standard. While this promises streamlined compliance for manufacturers, it also introduces subtle but critical new challenges.

This episode goes beyond the surface-level news of harmonization. We uncover the dangerous assumption that existing ISO 13485 certification equals automatic QMSR compliance and highlight the specific gaps that could lead to inspection failures.

A real-world example is a device manufacturer with CE marking and ISO 13485 certification. They enter the US market assuming they are ready for the new QMSR. During an FDA inspection, they receive a warning letter because their risk management process, while compliant for the EU, isn't integrated into their supply chain and production controls as required by the FDA's interpretation. This is the hidden pain point this episode addresses.

Key Questions Answered:

- Why isn't your current ISO 13485 certificate a free pass for the new FDA QMSR?

- What specific FDA requirements are not covered by the standard ISO 13485?

- How does the QMSR change the FDA's approach to risk management during inspections?

- What is the single biggest mistake companies make when updating their QMS?

- How must you adapt your supplier management and design controls to comply?

- What are the new expectations for management responsibility and documentation?

- Is your risk management a continuous process or just a static document?

Contact us at [email protected] or visit https://pureglobal.com/ or visit https://pureglobal.ai/ for FREE AI tools and a free medical device database.